logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Monday, February 2, 2026 · 888,728,999 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Pharmaceutical Industry Second Half Profits News Monitoring

  • Published on 06:33 GMT

    Alteogen’s operating profit surges 275% in 2025 on tech export deals

    Alteogen, a Korean biotech listed on the Kosdaq, reported record earnings for 2025 on a standalone basis, posting revenue of 202.1 billion won ($138.5 million) and operating profit of 114.8 billion won, the company said Monday. Revenue more than doubled …

    Source: Korea Biomedical Review - Neutral
  • Published on 01:33 GMT

    Lunit shifts to profitability-first strategy with ₩250 bil. rights offering

    Lunit, a medical AI company, has declared a definitive shift from aggressive expansion to substantial profitability, backed by a massive 250 billion won ($185.4 million) capital raise plan. The company announced that this shareholder-allocated rights …

    Source: Korea Biomedical Review - Neutral
  • Published on 11:03 GMT

    Economic Outlook: Building more resilient and diverse portfolios in 2026

    This content has been supplied by a commercial partner.   As we enter 2026, the global economy looks to be in better shape than many feared last April, with recession risks receding. However, the landscape is more fragile than the headlines suggest. …

    Source: Civil Society Media - Center-left
  • Published on Jan 31, 2026

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.44, expectations were $10.74. Operator: Welcome to the Regeneron …

    Source: Insider Monkey - Neutral
  • Published on Jan 30, 2026

    Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2026 Earnings Call Transcript

    Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2026 Earnings Call Transcript January 29, 2026 Takeda Pharmaceutical Company Limited misses on earnings expectations. Reported EPS is $0.2151 EPS, expectations were $0.55. Christopher David O’Reilly: [ …

    Source: Insider Monkey - Neutral
  • Published on Jan 29, 2026

    Roche’s 2025 profit blunted by weakened US dollar

    Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the drugmaker reporting strong growth for food allergy medicine Xolair (omalizumab) and multiple sclerosis treatment Ocrevus (ocrelizumab). …

    Source: Pharmaceutical Technology - Pending
  • Published on Jan 29, 2026

    Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2025 Earnings Call Transcript

    Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2025 Earnings Call Transcript January 28, 2026 Teva Pharmaceutical Industries Limited beats earnings expectations. Reported EPS is $0.96, expectations were $0.65. Operator: Hello, and welcome to the …

    Source: Insider Monkey - Neutral
  • Published on Jan 30, 2026

    Radiologists continue to dominate in No Surprises Act payment disputes

    Radiologists and other physicians continue to dominate in payment disputes with health insurers under the No Surprises Act.  The federal government recently released new data pertaining to the landmark legislation, meant to protect patients from receiving …

    Source: Health Imaging - Neutral
  • Published on Jan 30, 2026

    SMALL CAP MOVERS: London BTC launches gold hedging strategy

    There are few storytellers and yarn spinners as deft as the small cap market's perennial dealmakers.  For every cycle, trend and fad, some closely followed execs tend to find an angle for the small cap investment audience. So it is then, that as gold …

    Source: Daily Mail - Right-wing
  • Published on Jan 31, 2026

    This FTSE 100 stock could be poised for a whopping 40% growth in 2026, or more

    Free Article You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, …

    Source: The Motley Fool UK - Neutral
  • Published on Jan 30, 2026

    Trane Technologies plc (NYSE:TT) Q4 2025 Earnings Call Transcript

    Trane Technologies plc (NYSE:TT) Q4 2025 Earnings Call Transcript January 29, 2026 Trane Technologies plc beats earnings expectations. Reported EPS is $2.86, expectations were $2.81. Operator: Good morning, and welcome to the Trane Technologies Fourth …

    Source: Insider Monkey - Neutral
  • Published on Jan 30, 2026

    North Korea’s 2025 Health Revolution

    In a significant policy pivot amid ongoing economic sanctions, Kim Jong Un designated 2025 as the “First Year of the Health Revolution,” launching an aggressive campaign to construct modern hospitals in cities and counties nationwide. This initiative is …

    Source: 38 North - Neutral
  • Published on Jan 29, 2026

    Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth

    Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med Vyvanse. Now that the gap between Vyvanse erosion and growth from new products is narrowing, Takeda is eager to move into its next …

    Source: Fierce Pharma - Neutral
  • Published on Jan 29, 2026

    Hims & Hers Fights The Rich, Serena Touts Ro, In SB Telehealth Ads

      For the second straight year, telehealth provider Hims & Hers will stake out a controversial position in its Super Bowl ad, while competitor Ro will make its Big Game debut with a celebrity-driven spot starring Serena Williams. Hims & Hers A year …

    Source: MediaPost - Neutral
  • Published on Jan 29, 2026

    Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript

    Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript January 28, 2026 Danaher Corporation beats earnings expectations. Reported EPS is $2.23, expectations were $2.16. Operator: To all sites on hold, we would like to thank you for your patience. …

    Source: Insider Monkey - Neutral
  • Published on Jan 29, 2026

    Exceptional demand, while earnings weakened: Report by Munters Group AB

    STOCKHOLM, Jan. 29, 2026 /PRNewswire/ -- Divestment of the FoodTech Equipment offering has been completed. The comments and figures in this report refer to continuing operations unless otherwise stated. For more information, see pages 17-18. …

    Source: WFMZ - Pennsylvania - Neutral
  • Published on Jan 30, 2026

    Sanofi touts strong new launch sales amid looming Dupixent patent expiry

    Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of its best-selling asset, Dupixent (dupilumab). In FY2025, the French pharmaceutical company achieved net sales of €43.6bn ($51.9bn) – …

    Source: Pharmaceutical Technology - Pending
  • Published on Jan 30, 2026

    Scott Power: Quarterly results build momentum for ASX healthcare stocks

    ASX healthcare companies have been laying foundations for growth. Pic:Getty Images ASX health sector up 0.11% for the week, while broader market rises 0.23% Week dominated by quarterly results with several companies reaching key milestones  Morgans …

    Source: Stockhead - Neutral
  • «
  • 1
  • »

07 days 08:54:04

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 888,728,999 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 01/13/2026

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow EIN Presswire on Facebook, LinkedIn and Substack

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2026 Newsmatics Inc. · All Rights Reserved · General Terms & Conditions · Privacy Policy · Cookie Settings

By continuing to use this site, you agree to our Terms & Conditions, last updated on September 30, 2025.